Introduction: Adenoid cystic carcinoma (ACC) of the head and neck is a rare malignancy of the salivary glands that accounts for approximately 10% of salivary gland carcinoma. Despite aggressive local therapy, local recurrence and distant metastases occur frequently. Response rates (RR) to potential curative and palliative chemotherapy are limited, so new strategies are needed.
Case reports: We describe five case reports of patients with unresectable locally advanced or metastatic ACC of the head and neck who have been treated with sorafenib, a multi-tyrosine kinase inhibitor (mTKI).
Results: In this case series, we found that three out of five patients treated with sorafenib survived, respectively, 16, 35 and 35 months. Two patients showed a partial response (PR) and one patient had a prolonged stable disease (SD) for almost three years. Grade 3 adverse events (AE) occur under sorafenib so adequate toxicity management is essential. This retrospective case series hints towards the possibility of clinical benefit for treating ACC patients with sorafenib. Efficacy of sorafenib should be studied in a prospective-randomized clinical trial which is a challenging task due to the rarity of the disease.
{"title":"Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.","authors":"Karen Couvreur, Jacobs Celine, Bock Marlies, D'Hondt Randal, Deron Philippe, Duprez Frederic, Rottey Sylvie","doi":"10.1080/17843286.2019.1633490","DOIUrl":"https://doi.org/10.1080/17843286.2019.1633490","url":null,"abstract":"<p><strong>Introduction: </strong>Adenoid cystic carcinoma (ACC) of the head and neck is a rare malignancy of the salivary glands that accounts for approximately 10% of salivary gland carcinoma. Despite aggressive local therapy, local recurrence and distant metastases occur frequently. Response rates (RR) to potential curative and palliative chemotherapy are limited, so new strategies are needed.</p><p><strong>Case reports: </strong>We describe five case reports of patients with unresectable locally advanced or metastatic ACC of the head and neck who have been treated with sorafenib, a multi-tyrosine kinase inhibitor (mTKI).</p><p><strong>Results: </strong>In this case series, we found that three out of five patients treated with sorafenib survived, respectively, 16, 35 and 35 months. Two patients showed a partial response (PR) and one patient had a prolonged stable disease (SD) for almost three years. Grade 3 adverse events (AE) occur under sorafenib so adequate toxicity management is essential. This retrospective case series hints towards the possibility of clinical benefit for treating ACC patients with sorafenib. Efficacy of sorafenib should be studied in a prospective-randomized clinical trial which is a challenging task due to the rarity of the disease.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 5","pages":"362-369"},"PeriodicalIF":1.6,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1633490","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37355745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-01Epub Date: 2019-05-29DOI: 10.1080/17843286.2019.1623516
J Paul, F Vaillant, O Vanden Bossche, T Pepersack, S Henrard, B Boland
Objectives: . To investigate the dose-response relationship between cardiovascular or psychotropic medication dosages and falling orthostatic blood pressure in geriatric inpatients.
Methods: . This cross-sectional study included 100 consecutive geriatric inpatients of a Belgian hospital. The end points were the maximum changes of systolic (sBP) and diastolic (dBP) blood pressure in a standing up position at one or three minutes. The dosages of six classes of vascular and five classes of psychotropic medications were expressed in terms of a proportion of defined daily doses (DDD). Bivariate and multivariate linear regression models were used.
Results: . The 100 geriatric patients (85 ± 5 years, 58 % women) received 7.7 ± 4 medications (mean DDD: vascular = 1.0, psychotropic = 0.74) on the day of an orthostatic test (lying sBP: 136 ± 21; dBP: 72 ± 14 mm Hg). In a standing position, sBP and dBP fell by 12 ± 17 and 11 ± 5 mmHg, respectively. At the individual level, BP change was not correlated with vascular DDD (sBP: p = 0.07, r2 = 0.04; dBP: p = 0.59; r2 = 0.004) nor with psychotropic DDD (sBP: p = 0.14, r2 = 0.02; dBP: p = 0.82; r2 = 0.0). In multivariate analysis, sBP drop was positively associated with age, diabetes, falls history, and number of medications, but not with the DDD of any of the medication classes, while dBP drop was positively associated with age, diabetes, stroke and anaemia, but again with the DDD of any of the medication classes.
Conclusion: . No correlation was found between vascular and psychotropic medication dosages and the orthostatic blood pressure drop expressed as a continuous variable.
目的:。探讨老年住院患者心血管或精神药物剂量与体位血压下降的剂量-反应关系。方法:。本横断面研究包括100名连续在比利时一家医院住院的老年患者。终点是站立位1分钟或3分钟时收缩压(sBP)和舒张压(dBP)的最大变化。六类血管药物和五类精神药物的剂量以限定日剂量(DDD)的比例表示。采用双变量和多变量线性回归模型。结果:。100例老年患者(85±5岁,58%为女性)在直立试验当天接受了7.7±4种药物治疗(平均DDD:血管= 1.0,精神药物= 0.74)(卧位收缩压:136±21;dBP: 72±14mmhg)。站立时收缩压和舒张压分别下降12±17和11±5 mmHg。在个体水平上,血压变化与血管DDD无相关性(sBP: p = 0.07, r2 = 0.04;dBP: p = 0.59;r2 = 0.004)与精神类DDD无关(sBP: p = 0.14, r2 = 0.02;dBP: p = 0.82;r2 = 0.0)。在多变量分析中,收缩压下降与年龄、糖尿病、跌倒史和药物数量呈正相关,但与任何药物类别的DDD无关,而舒张压下降与年龄、糖尿病、中风和贫血呈正相关,但与任何药物类别的DDD呈正相关。结论:。血管和精神药物剂量与体位血压降之间没有相关性,体位血压降表现为连续变量。
{"title":"Orthostatic blood pressure drop and cardiovascular and psychotropic medication dosages in acutely ill geriatric inpatients.","authors":"J Paul, F Vaillant, O Vanden Bossche, T Pepersack, S Henrard, B Boland","doi":"10.1080/17843286.2019.1623516","DOIUrl":"https://doi.org/10.1080/17843286.2019.1623516","url":null,"abstract":"<p><strong>Objectives: </strong>. To investigate the dose-response relationship between cardiovascular or psychotropic medication dosages and falling orthostatic blood pressure in geriatric inpatients.</p><p><strong>Methods: </strong>. This cross-sectional study included 100 consecutive geriatric inpatients of a Belgian hospital. The end points were the maximum changes of systolic (sBP) and diastolic (dBP) blood pressure in a standing up position at one or three minutes. The dosages of six classes of vascular and five classes of psychotropic medications were expressed in terms of a proportion of defined daily doses (DDD). Bivariate and multivariate linear regression models were used.</p><p><strong>Results: </strong>. The 100 geriatric patients (85 ± 5 years, 58 % women) received 7.7 ± 4 medications (mean DDD: vascular = 1.0, psychotropic = 0.74) on the day of an orthostatic test (lying sBP: 136 ± 21; dBP: 72 ± 14 mm Hg). In a standing position, sBP and dBP fell by 12 ± 17 and 11 ± 5 mmHg, respectively. At the individual level, BP change was not correlated with vascular DDD (sBP: p = 0.07, r<sup>2</sup> = 0.04; dBP: p = 0.59; r<sup>2</sup> = 0.004) nor with psychotropic DDD (sBP: p = 0.14, r<sup>2</sup> = 0.02; dBP: p = 0.82; r<sup>2</sup> = 0.0). In multivariate analysis, sBP drop was positively associated with age, diabetes, falls history, and number of medications, but not with the DDD of any of the medication classes, while dBP drop was positively associated with age, diabetes, stroke and anaemia, but again with the DDD of any of the medication classes.</p><p><strong>Conclusion: </strong>. No correlation was found between vascular and psychotropic medication dosages and the orthostatic blood pressure drop expressed as a continuous variable.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 5","pages":"313-320"},"PeriodicalIF":1.6,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1623516","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37288674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-01Epub Date: 2019-06-11DOI: 10.1080/17843286.2019.1629077
Ine Van Bogaert, Catheline Depuydt, Said Hachimi-Idrissi
Objectives: Emergency physicians have shown difficulties to combine their private and professional life. In addition to a very stressful environment, they have to deal with multiple sources of uncertainty. These factors may lead to psychological distress. The aim of this study is to determine the factors leading to dissatisfaction and burnout among Flemish emergency physicians (EPs). Which are the barriers hindering EPs to seek help and what are the potential solutions for this problem? Methods:This is a prospective, explorative qualitative study where seven Flemish EPs were interviewed. These were in-depth semi-structured interviews. The information from the interviews was analyzed using NVivo 12. Results:The common contributors were the working schedule, the increasing number of patients, the mental and physical impact of the job and the relatively low income. The most important barrier to seek help is the existence of an unforgiving medical culture. The solutions provided by the EPs are less patients and a better financing. Conclusion:Dissatisfaction and burnout are common among the EP profession. There is a need for awareness and a change in the unforgiving medical culture to a 'no shame no blame culture'. Improvement of EPs' work schedule and income to the level of other medical specialties are other important needs. Finally, reducing the number of patient contact at the emergency department, by highlighting the difference between medical urgency rather than personal convenience.
{"title":"Dissatisfaction and Burnout among Flemish emergency physicians: a qualitative study.","authors":"Ine Van Bogaert, Catheline Depuydt, Said Hachimi-Idrissi","doi":"10.1080/17843286.2019.1629077","DOIUrl":"https://doi.org/10.1080/17843286.2019.1629077","url":null,"abstract":"<p><strong>Objectives: </strong>Emergency physicians have shown difficulties to combine their private and professional life. In addition to a very stressful environment, they have to deal with multiple sources of uncertainty. These factors may lead to psychological distress. The aim of this study is to determine the factors leading to dissatisfaction and burnout among Flemish emergency physicians (EPs). Which are the barriers hindering EPs to seek help and what are the potential solutions for this problem? <b>Methods:</b>This is a prospective, explorative qualitative study where seven Flemish EPs were interviewed. These were in-depth semi-structured interviews. The information from the interviews was analyzed using NVivo 12. <b>Results:</b>The common contributors were the working schedule, the increasing number of patients, the mental and physical impact of the job and the relatively low income. The most important barrier to seek help is the existence of an unforgiving medical culture. The solutions provided by the EPs are less patients and a better financing. <b>Conclusion:</b>Dissatisfaction and burnout are common among the EP profession. There is a need for awareness and a change in the unforgiving medical culture to a 'no shame no blame culture'. Improvement of EPs' work schedule and income to the level of other medical specialties are other important needs. Finally, reducing the number of patient contact at the emergency department, by highlighting the difference between medical urgency rather than personal convenience.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 5","pages":"329-333"},"PeriodicalIF":1.6,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1629077","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37319948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare autoimmune disorder characterized by auto-antibodies to Willebrand factor (vWF) cleaving enzyme (ADAMTS13), resulting in unusually large vWF multimers that lead to platelet aggregation, microthrombi formation and microangiopathic hemolytic anemia. Hemolysis in aTTP is mechanical; thus, direct antiglobulin test (Coombs test) is usually negative. Multiple autoimmune conditions and various auto-antibodies have been described in the context of chronic myelomonocytic leukemia (CMML). In this paper, we describe the first case of CMML with auto-antibodies to ADAMTS13, presenting initially as plasmapheresis-refractory Coombs-positive aTTP. Results: Although our patient was not treated for CMML, a complete remission of aTTP was eventually achieved with rituximab. Conclusion; We propose that aTTP should be in the differential diagnosis of CMML patients with thrombocytopenia and anemia (Coombs positive or not) who develop signs of thrombotic microangiopathy. Further studies are much needed to decipher the immune-mediated processes in CMML.
{"title":"Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab.","authors":"Ivan Krecak, Marijana Grgic Medic, Velka Gveric-Krecak, Pavle Roncevic, Sandra Bašić Kinda, Jaksa Babel, Radovan Radonic","doi":"10.1080/17843286.2019.1608395","DOIUrl":"https://doi.org/10.1080/17843286.2019.1608395","url":null,"abstract":"<p><strong>Objectives: </strong>Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare autoimmune disorder characterized by auto-antibodies to Willebrand factor (vWF) cleaving enzyme (ADAMTS13), resulting in unusually large vWF multimers that lead to platelet aggregation, microthrombi formation and microangiopathic hemolytic anemia. Hemolysis in aTTP is mechanical; thus, direct antiglobulin test (Coombs test) is usually negative. Multiple autoimmune conditions and various auto-antibodies have been described in the context of chronic myelomonocytic leukemia (CMML). In this paper, we describe the first case of CMML with auto-antibodies to ADAMTS13, presenting initially as plasmapheresis-refractory Coombs-positive aTTP. <b>Results:</b> Although our patient was not treated for CMML, a complete remission of aTTP was eventually achieved with rituximab. Conclusion; We propose that aTTP should be in the differential diagnosis of CMML patients with thrombocytopenia and anemia (Coombs positive or not) who develop signs of thrombotic microangiopathy. Further studies are much needed to decipher the immune-mediated processes in CMML.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 5","pages":"357-361"},"PeriodicalIF":1.6,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1608395","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37173030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-01Epub Date: 2019-07-01DOI: 10.1080/17843286.2019.1637389
Katrien Benhalima, Caro Minschart, Paul Van Crombrugge, Peggy Calewaert, Johan Verhaeghe, Siska Vandamme, Katrien Theetaert, Roland Devlieger, Leen Pierssens, Hannah Ryckeghem, Els Dufraimont, Chris Vercammen, Ann Debie, Christophe De Block, Griet Vandenberghe, Sylva Van Imschoot, Sabine Verstraete, Luk Buyse, Johan Wens, Joke Muyldermans, Anissa Meskal, Sandy De Spiegeleer, Chantal Mathieu
Screening for gestational diabetes mellitus (GDM) is important to improve pregnancy outcomes and to prevent type 2 diabetes after pregnancy. The 'International Association of Diabetes and Pregnancy Study Groups' (IADPSG) recommends a universal one-step approach with the 75 g oral glucose tolerance test (OGTT) for screening of GDM. The IADPSG recommendation remains controversial due to the important increase in GDM prevalence and increased workload. After review of the latest evidence and based on data from the 'Belgian Diabetes in Pregnancy' study, members of the Diabetes Liga, the Flemish associations of general physicians (Domus Medica), obstetricians (VVOG), midwives (VVOB), diabetes nurse educators (BVVDV) and clinical chemists (RBSLM) have reached a new consensus on screening for GDM in Flanders. This new consensus recommends universal screening for overt diabetes when planning pregnancy or at the latest at first prenatal contact, preferably by measuring the fasting plasma glucose by using the same diagnostic criteria as in the non-pregnant state. In women with impaired fasting glycaemia, but also in normoglycemic obese women and women with a previous history of GDM, lifestyle counselling is advised with screening for GDM with a 75 g OGTT at 24 weeks. In all other women, we recommend a two-step screening strategy with a 50 g glucose challenge test (GCT) at 24 weeks followed by a 75 g OGTT when the glucose level 1 hour after the GCT ≥130 mg/dl. Diagnosis of GDM is made using the IADPSG criteria for GDM. Postpartum screening for subsequent glucose abnormalities should be advocated and organized for every woman with GDM.
妊娠期糖尿病(GDM)筛查对改善妊娠结局和预防妊娠后2型糖尿病具有重要意义。“国际糖尿病和妊娠研究小组协会”(IADPSG)推荐一种通用的一步法,即75g口服葡萄糖耐量试验(OGTT)筛查GDM。由于GDM患病率的显著增加和工作量的增加,IADPSG的建议仍然存在争议。在回顾了最新的证据和基于“比利时妊娠糖尿病”研究的数据后,糖尿病联盟的成员、佛兰德全科医生协会(Domus Medica)、产科医生协会(VVOG)、助产士协会(VVOB)、糖尿病护士教育者协会(BVVDV)和临床化学家协会(RBSLM)就佛兰德的GDM筛查达成了新的共识。这一新的共识建议在计划怀孕时或最迟在产前第一次接触时对显性糖尿病进行普遍筛查,最好是通过使用与未怀孕状态相同的诊断标准测量空腹血糖。对于空腹血糖受损的女性,以及血糖正常的肥胖女性和既往有GDM病史的女性,建议进行生活方式咨询,并在24周时进行75 g OGTT筛查GDM。对于所有其他女性,我们建议采用两步筛查策略,在24周时进行50g葡萄糖激发试验(GCT),然后在GCT后1小时血糖水平≥130mg /dl时进行75g OGTT。GDM的诊断是使用GDM的IADPSG标准进行的。产后筛查后续血糖异常应提倡和组织每一个妇女的GDM。
{"title":"The 2019 Flemish consensus on screening for overt diabetes in early pregnancy and screening for gestational diabetes mellitus.","authors":"Katrien Benhalima, Caro Minschart, Paul Van Crombrugge, Peggy Calewaert, Johan Verhaeghe, Siska Vandamme, Katrien Theetaert, Roland Devlieger, Leen Pierssens, Hannah Ryckeghem, Els Dufraimont, Chris Vercammen, Ann Debie, Christophe De Block, Griet Vandenberghe, Sylva Van Imschoot, Sabine Verstraete, Luk Buyse, Johan Wens, Joke Muyldermans, Anissa Meskal, Sandy De Spiegeleer, Chantal Mathieu","doi":"10.1080/17843286.2019.1637389","DOIUrl":"https://doi.org/10.1080/17843286.2019.1637389","url":null,"abstract":"<p><p>Screening for gestational diabetes mellitus (GDM) is important to improve pregnancy outcomes and to prevent type 2 diabetes after pregnancy. The 'International Association of Diabetes and Pregnancy Study Groups' (IADPSG) recommends a universal one-step approach with the 75 g oral glucose tolerance test (OGTT) for screening of GDM. The IADPSG recommendation remains controversial due to the important increase in GDM prevalence and increased workload. After review of the latest evidence and based on data from the 'Belgian Diabetes in Pregnancy' study, members of the Diabetes Liga, the Flemish associations of general physicians (Domus Medica), obstetricians (VVOG), midwives (VVOB), diabetes nurse educators (BVVDV) and clinical chemists (RBSLM) have reached a new consensus on screening for GDM in Flanders. This new consensus recommends universal screening for overt diabetes when planning pregnancy or at the latest at first prenatal contact, preferably by measuring the fasting plasma glucose by using the same diagnostic criteria as in the non-pregnant state. In women with impaired fasting glycaemia, but also in normoglycemic obese women and women with a previous history of GDM, lifestyle counselling is advised with screening for GDM with a 75 g OGTT at 24 weeks. In all other women, we recommend a two-step screening strategy with a 50 g glucose challenge test (GCT) at 24 weeks followed by a 75 g OGTT when the glucose level 1 hour after the GCT ≥130 mg/dl. Diagnosis of GDM is made using the IADPSG criteria for GDM. Postpartum screening for subsequent glucose abnormalities should be advocated and organized for every woman with GDM.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 5","pages":"340-347"},"PeriodicalIF":1.6,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1637389","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37382410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-01Epub Date: 2019-06-18DOI: 10.1080/17843286.2019.1630109
Lynn Ghijselings, Dirk Van De Putte, François Hervé, An-Sofie Goessaert, Dimitri Beeckman, Piet Pattyn, Karel Everaert
Introduction/background: The management of therapy-resistant lower urinary tract symptoms (LUTS) and symptoms resulting from pelvic organ dysfunctions are subject to a high variability in the Belgian health-care centres. Practical guidelines and standardized patient clinical care pathways are often lacking and unadapted to the Belgian healthcare system.
Objectives: The OptiLUTS trial aims to improve the multidisciplinary care of therapy-resistant symptoms of the pelvis in the Belgian healthcare setting. Project A aims for the improvement of knowledge of 2nd line treatments for LUTS among general practitioners. In project B a treatment algorithm for the overactive bladder syndrome and non-obstructive urinary retention will be developed specifically for Belgium. In Project C a patient customized sacral neuromodulation (SNM) care pathway will be set up.
Methods: Part A: Explorative study among general practitioners by distribution of a questionnaire. Part B: Review of existing guidelines and use of the Delphi method to obtain expert consensus. Part C: A single center comparative study to compare outcomes before and after implementation of the SNM care pathway. Patients scheduled for the first stage of Interstim therapy™ will be included (N=100). Primary endpoints are the sensitivity and specificity of a new pelvic symptom assessment tool, the conversion to implant and explantation rates.
Conclusion: There is a margin for improvement in the care process of patients with therapy-resistant symptoms of the pelvis in the Belgium healthcare system. In the OptiLUTs trial adapted guidelines and a clinical care pathway will be developed to standardize and increase the efficiency of care.
Trial registration: Approval for the trial by the Ethics Committee of the Ghent University hospital: EC/2018/0244.
{"title":"The OptiLUTS trial: improving care for therapy-resistant symptoms of the pelvis in Belgium.","authors":"Lynn Ghijselings, Dirk Van De Putte, François Hervé, An-Sofie Goessaert, Dimitri Beeckman, Piet Pattyn, Karel Everaert","doi":"10.1080/17843286.2019.1630109","DOIUrl":"https://doi.org/10.1080/17843286.2019.1630109","url":null,"abstract":"<p><strong>Introduction/background: </strong>The management of therapy-resistant lower urinary tract symptoms (LUTS) and symptoms resulting from pelvic organ dysfunctions are subject to a high variability in the Belgian health-care centres. Practical guidelines and standardized patient clinical care pathways are often lacking and unadapted to the Belgian healthcare system.</p><p><strong>Objectives: </strong>The OptiLUTS trial aims to improve the multidisciplinary care of therapy-resistant symptoms of the pelvis in the Belgian healthcare setting. Project A aims for the improvement of knowledge of 2nd line treatments for LUTS among general practitioners. In project B a treatment algorithm for the overactive bladder syndrome and non-obstructive urinary retention will be developed specifically for Belgium. In Project C a patient customized sacral neuromodulation (SNM) care pathway will be set up.</p><p><strong>Methods: </strong>Part A: Explorative study among general practitioners by distribution of a questionnaire. Part B: Review of existing guidelines and use of the Delphi method to obtain expert consensus. Part C: A single center comparative study to compare outcomes before and after implementation of the SNM care pathway. Patients scheduled for the first stage of Interstim therapy™ will be included (N=100). Primary endpoints are the sensitivity and specificity of a new pelvic symptom assessment tool, the conversion to implant and explantation rates.</p><p><strong>Conclusion: </strong>There is a margin for improvement in the care process of patients with therapy-resistant symptoms of the pelvis in the Belgium healthcare system. In the OptiLUTs trial adapted guidelines and a clinical care pathway will be developed to standardize and increase the efficiency of care.</p><p><strong>Trial registration: </strong>Approval for the trial by the Ethics Committee of the Ghent University hospital: EC/2018/0244.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 5","pages":"334-339"},"PeriodicalIF":1.6,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1630109","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37338049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-08-01Epub Date: 2019-05-05DOI: 10.1080/17843286.2019.1613309
Sebastiaan Dhont, Mathias Leys, Edward De Sutter, Herwig Alaerts, Wouter Van Moerkercke
Sarcoidosis is a multisystem disease of unclear etiology with a variable clinical profile characterized by the presence of non-caseating granuloma in involved organs. The diagnosis is often challenging and based on clinical, radiological and anatomopathological data. Sarcoidosis can be benign and self-limiting, but some cases may follow a chronic, progressive course and result in severe morbidity. The disease has a predilection for the lungs and thoracic lymph nodes but can involve nearly any part of the body, possible more commonly in areas with contact to the external environment, such as the eyes and the skin. This paper is based on a case in which a recurrent uveitis led to the diagnosis of an underlying sarcoidosis.
{"title":"Uveitis as a window to diagnosis of sarcoidosis - case report and review of the literature.","authors":"Sebastiaan Dhont, Mathias Leys, Edward De Sutter, Herwig Alaerts, Wouter Van Moerkercke","doi":"10.1080/17843286.2019.1613309","DOIUrl":"https://doi.org/10.1080/17843286.2019.1613309","url":null,"abstract":"<p><p>Sarcoidosis is a multisystem disease of unclear etiology with a variable clinical profile characterized by the presence of non-caseating granuloma in involved organs. The diagnosis is often challenging and based on clinical, radiological and anatomopathological data. Sarcoidosis can be benign and self-limiting, but some cases may follow a chronic, progressive course and result in severe morbidity. The disease has a predilection for the lungs and thoracic lymph nodes but can involve nearly any part of the body, possible more commonly in areas with contact to the external environment, such as the eyes and the skin. This paper is based on a case in which a recurrent uveitis led to the diagnosis of an underlying sarcoidosis.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 4","pages":"245-249"},"PeriodicalIF":1.6,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1613309","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37211774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-08-01Epub Date: 2019-03-28DOI: 10.1080/17843286.2019.1599549
Dimitri Poddighe
Dear Sir, I read with great interest the case report by Matthys I et al., describing a young adult patient with acute, sudden and severe clinical manifestations that the authors were able to correl...
{"title":"Hyperferritinemia, vasculitis and <i>Mycoplasma pneumoniae</i>.","authors":"Dimitri Poddighe","doi":"10.1080/17843286.2019.1599549","DOIUrl":"https://doi.org/10.1080/17843286.2019.1599549","url":null,"abstract":"Dear Sir, I read with great interest the case report by Matthys I et al., describing a young adult patient with acute, sudden and severe clinical manifestations that the authors were able to correl...","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 4","pages":"311"},"PeriodicalIF":1.6,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1599549","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37100531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-08-01Epub Date: 2019-03-28DOI: 10.1080/17843286.2019.1599569
Daniel Borsboom, Imke Matthys, Christophe Van Steenkiste
Dear Editor, We would like to comment on additional concerns that may rise about our manuscript ‘A plethora of manifestations following a Mycoplasma pneumoniae infection: a case report’[1]: 1. Rega...
{"title":"Hyperferritinemia associated with systemic manifestations of Mycoplasma pneumoniae infection.","authors":"Daniel Borsboom, Imke Matthys, Christophe Van Steenkiste","doi":"10.1080/17843286.2019.1599569","DOIUrl":"https://doi.org/10.1080/17843286.2019.1599569","url":null,"abstract":"Dear Editor, We would like to comment on additional concerns that may rise about our manuscript ‘A plethora of manifestations following a Mycoplasma pneumoniae infection: a case report’[1]: 1. Rega...","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 4","pages":"312"},"PeriodicalIF":1.6,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1599569","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37099320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-08-01Epub Date: 2019-03-28DOI: 10.1080/17843286.2019.1595836
Barbara Geerinckx, Rachel Hellemans, Amaryllis H Van Craenenbroeck, Sven Francque, Liesbeth De Waele, Jeroen Kerstens, Pieter-Jan Van Gaal, Bart Bracke, Peter Michielsen, Thomas Vanwolleghem
Hemodialysis-related portosystemic encephalopathy (HRPSE) is a clinical phenomenon where portosystemic encephalopathy (PSE) develops without liver dysfunction, usually caused by changes in the portosystemic blood flow related to hemodialysis. We describe the case of a 22-year old patient with a transjugular intrahepatic portosystemic shunt (TIPS) who developed HRPSE several months after initiation of hemodialysis. Despite initial therapy with laxatives and neomycin symptoms recurred. It was only after relocation of the hemodialysis catheter from the superior caval vein to the femoral vein that symptoms completely resolved.
{"title":"A rare case of hemodialysis-related portosystemic encephalopathy and review of the literature.","authors":"Barbara Geerinckx, Rachel Hellemans, Amaryllis H Van Craenenbroeck, Sven Francque, Liesbeth De Waele, Jeroen Kerstens, Pieter-Jan Van Gaal, Bart Bracke, Peter Michielsen, Thomas Vanwolleghem","doi":"10.1080/17843286.2019.1595836","DOIUrl":"https://doi.org/10.1080/17843286.2019.1595836","url":null,"abstract":"<p><p>Hemodialysis-related portosystemic encephalopathy (HRPSE) is a clinical phenomenon where portosystemic encephalopathy (PSE) develops without liver dysfunction, usually caused by changes in the portosystemic blood flow related to hemodialysis. We describe the case of a 22-year old patient with a transjugular intrahepatic portosystemic shunt (TIPS) who developed HRPSE several months after initiation of hemodialysis. Despite initial therapy with laxatives and neomycin symptoms recurred. It was only after relocation of the hemodialysis catheter from the superior caval vein to the femoral vein that symptoms completely resolved.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":"75 4","pages":"296-300"},"PeriodicalIF":1.6,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/17843286.2019.1595836","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37098188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}